A Phase 2, Open Label, Pilot Study to Examine the Use of Rivaroxaban Plus Aspirin vs. Clopidogrel Plus Aspirin for the Prevention of Restenosis After Infrainguinal Percutaneous Transluminal Angioplasty for Critical Limb Ischemia

Trial Profile

A Phase 2, Open Label, Pilot Study to Examine the Use of Rivaroxaban Plus Aspirin vs. Clopidogrel Plus Aspirin for the Prevention of Restenosis After Infrainguinal Percutaneous Transluminal Angioplasty for Critical Limb Ischemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel
  • Indications Peripheral arterial disorders; Peripheral artery restenosis
  • Focus Adverse reactions
  • Acronyms RIVAL-PAD
  • Most Recent Events

    • 19 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top